FGFR2 and cholangiocarcinoma: A post-hoc analysis of FIGHT-202 data suggests that patients with CCA and FGFR2 fusions or rearrangements treated with second-line pemigatinib might experience longer PFS compared to classic cytostatic systemic therapy [122].